Hematology Reports, Volume 15, Issue 4
2023 December - 15 articles
Cover Story: Acute myeloid leukemia (AML) is a difficult-to-treat cancer that is prone to drug resistance. Chimeric antigen receptor T cell (CAR-T) therapy provides a reasonable alternative in AML that has shown great success in other diseases, such as lymphoid malignancies or non-malignant refractory systemic lupus erythematosus. AML patients have not yet responded well to current CAR-T treatments, and several clinical trials are ongoing. We provide an overview of basic concepts of CAR-T cell therapy and current approaches in AML, review current strategies to improve treatment efficacies, and analyze the antigen landscape that is targeted in AML. While CAR-T cell therapy has not come to clinical fruition, a better understanding of the mechanisms involved will provide clues on how to improve future approaches in AML. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.